Featured Press Releases

Aurora enhances Australian offerings with premium dried flower range

Aurora enhances Australian offerings with premium dried flower range

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

  • 09 Dec 2024

Biolexis Therapeutics, a leading metabolic drug discovery company focused on improving the lives...

IFF Pharma Solutions launches METHOCEL™ HPMC with low nitrite content to mitigate nitrosamine risks

IFF Pharma Solutions launches METHOCEL™ HPMC with low nitrite content to mitigate nitrosamine risks

Paragonix Celebrates a Major Milestone: 100 Kidney Transplants Powered by the FDA-Cleared KidneyVault™ System

Paragonix Celebrates a Major Milestone: 100 Kidney Transplants Powered by the FDA-Cleared KidneyVault™ System

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

  • Zeta Surgical
  • 23 Jun 2026
Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

  • Upsher-Smith Laboratories, LLC
  • 23 Jun 2026
Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

  • Piramal Pharma Solutions
  • 22 Jun 2026
Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

  • Gandeeva Therapeutics Inc.
  • 18 Jun 2026
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

  • Merck & Co., Inc.
  • 18 Jun 2026
Avenacy Announces the U.S. Launch of Bortezomib for Injection

Avenacy Announces the U.S. Launch of Bortezomib for Injection

  • Avenacy
  • 18 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.